Psych Congress 2017

The prevalence of SUDs is rising dramatically, with rates as high as 17 million for alcohol use disorder (AUD) and over 2 million for opioid use disorder (OUD). More than 100 American deaths per day are attributable to OUD alone. Despite available treatments, SUDs remain undertreated, perpetuating poor patient outcomes. This session will examine the latest research and evidence surrounding SUD treatment advances, including differences among oral and depot formulations, efficacy of available options within long-term management, implications on patient adherence, potential for illicit diversion, and associated genetic predilections to treatment response. In addition, as it is common for SUDs to co-exist with psychiatric disorders, evidence-based strategies for addressing concomitant SUD and other psychiatric disorders will be explored.

Supported by an educational grant from Alkermes, Inc. 

Recent research into the pathophysiology of MDD is revealing novel treatment targets that go beyond monoamines and include other targets, such as glutamate neurotransmission (e.g. ketamine and other modulators); modulation of cholinergic and gamma-aminobutyric acid (GABA)-ergic transmission; neuronal plasticity; stress/hypothalamic pituitary adrenal (HPA)-axis; neuroinflammation; and the reward system via modulation of opioid receptors and beta endorphins. In this session, Dr. Maletic will compare the safety and efficacy of novel MDD agents and their complementary role within the current treatment armamentarium.

Supported by an educational grant from Alkermes, Inc. 

Breakfast will be served. Seating for these sessions is available on a first-come, firstservedbasis. Admittance is based on availability and is not guaranteed. Please plan toarrive early to ensure a seat. Breakfast will only be available until 8 A.M.

Research into tardive dyskinesia (TD) pathophysiology and treatment targetshas led to the advancement of vesicular monoamine transporter 2 (VMAT2)inhibitors, with one agent recently approved by the FDA and the other grantedbreakthrough therapy designation. Key differences in the pharmacokinetic/pharmacodynamic properties of these newer agents will be examined, as wellas clinical outcome data from the ARM-TD, AIM- TD, KINECT-3, the ongoingKINECT-4, and other clinical trials.

Supported by an educational grant from Teva Pharmaceuticals.

Breakfast will be served. Seating for these sessions is available on a first-come, firstservedbasis. Admittance is based on availability and is not guaranteed. Please plan toarrive early to ensure a seat. Breakfast will only be available until 8 A.M.

Among the spectrum of mental health conditions, schizophrenia presents considerablechallenges in clinical management. Within schizophrenia, treatmentis not aligned with evolving best practices that now rank negative, cognitive,and mood symptomatology on par with classic positive symptoms. Many conventionalantipsychotic pharmacotherapies mainly address positive symptomsand are associated with adverse effects, contributing to incomplete treatmentand poor adherence. In this session, Drs. Citrome and Correll will identify thelimits of conventional schizophrenia pharmacotherapies in addressing thespectrum of symptom domains and tolerability in consideration for individualizedtreatment plans.

Supported by an educational grant from Allergan, Inc.

Breakfast will be served. Seating for these sessions is available on a first-come,first-served basis. Admittance is based on availability and is not guaranteed. Pleaseplan to arrive early to ensure a seat. Breakfast will only be available until 8 A.M.

Even though it is common, tardive dyskinesia (TD) is a neglected side effect ofthe atypical antipsychotics. This symposium will address the prevalence, diagnosisincluding AIMS examination, and evidence-based treatments for TD.

Supported by an educational grant from Neurocrine Biosciences.

Breakfast will be served. Seating for these sessions is available on a first-come, first-served basis.  Admittance is based on availability and is not guaranteed. Please plan to arrive early to ensure a seat. Breakfast will only be available until 8 A.M.

In this symposium, expert faculty will present case-based updates on the diagnosis and management of bipolar spectrum disorders in children and adolescents. The discussion will include practical approaches to diagnostic challenges, management of medical and psychiatric comorbidities, and evidence-based pharmacologic strategies.

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

Breakfast will be served. Seating for this session is available on a first-come, firstservedbasis. Admittance is based on availability and is not guaranteed. Please planto arrive early to ensure a seat. Breakfast will only be available until 8 A.M.

Nonadherence rates among persons with schizophrenia are estimated at 50%.Nonadherence to antipsychotic treatment is a primary reason for relapse and isassociated with increased hospitalization, higher risk of suicide, longer time toremission, poor prognosis, psychiatric emergencies, incarceration, and greaterhealthcare utilization. In this session, Drs. Kane and McEvoy will lead theaudience through a case-based analysis to identify challenges to adherence,outline pharmacotherapy interventions, and review shared decision makingprinciples designed to overcome prescription nonadherence and increasepatient outcomes.

Supported by an educational grant from Alkermes, Inc.